Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.32 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6909002 | 0.86 | CA1 (0.34) | CA1CA2CA4 | |
| SCHEMBL17696522 | 0.83 | — | — | |
| SCHEMBL9918285 | 0.80 | TRPA1 (0.35) | CA1CA2CA4PABPC1APOBEC3A | |
| SCHEMBL12418395 | 0.80 | TRPA1 (0.35) | CA1CA2CA4PABPC1APOBEC3A | |
| SCHEMBL12418390 | 0.80 | TRPA1 (0.35) | CA1CA2CA4PABPC1APOBEC3A | |
| SCHEMBL12418391 | 0.80 | TRPA1 (0.35) | CA1CA2CA4PABPC1APOBEC3A | |
| SCHEMBL12418393 | 0.80 | TRPA1 (0.35) | CA1CA2CA4PABPC1APOBEC3A | |
| SCHEMBL29107811 | 0.80 | CA1 (0.39) | CA1CA2CA4CYP1A2CYP2D6 | |
| SCHEMBL30492005 | 0.80 | CA1 (0.39) | CA1CA2CA4CYP1A2CYP2D6 | |
| SCHEMBL29107520 | 0.80 | CA1 (0.39) | CA1CA2CA4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732424-B2 | for reducing animal core temperatures and rate of oxygen consumption; protecting against myocardial damage during cardioplegia; cardiovascular disease, neurological disorders, ophthalmic conditions, ischemic conditions, reperfusion injury, obesity, wasting disease, and/or diabetes | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-06-08 | — | — | US | disclosed |
| US-20070191301-A1 | Purine derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191301-A1 | Purine derivatives and methods of use thereof | P2RY1, PNP, ADORA2A | CA1 2632/4885CA2 1860/4885CA4 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.